Michael Beck
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute · 378 works · 18,814 citations · h-index 73
Top works
- Recombinant human acid α-glucosidase
- Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey
- Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human α-L-iduronidase (laronidase)
- A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)
- Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy
- Anderson–Fabry disease: Clinical manifestations of disease in female heterozygotes
- Cumulative incidence rates of the mucopolysaccharidoses in Germany
- Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study
- Fabry Disease: Perspectives from 5 Years of FOS
- Cardiac manifestations of Anderson–Fabry disease in heterozygous females
- Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data
- Recognition and Diagnosis of Mucopolysaccharidosis II (Hunter Syndrome)
- Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey
- Fabry disease: overall effects of agalsidase alfa treatment
- Early Treatment With Alglucosidase Alfa Prolongs Long-Term Survival of Infants With Pompe Disease
- Long-term Efficacy and Safety of Laronidase in the Treatment of Mucopolysaccharidosis I
- The Mainz Severity Score Index: a new instrument for quantifying the Anderson–Fabry disease phenotype, and the response of patients to enzyme replacement therapy
- The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents
- The role of the iminosugar N‐butyldeoxynojirimycin (miglustat) in the management of type I (non‐neuronopathic) Gaucher disease: A position statement
- Enzyme Replacement Therapy in Patients Who Have Mucopolysaccharidosis I and Are Younger Than 5 Years: Results of a Multinational Study of Recombinant Human α- l -Iduronidase (Laronidase)